Guides Guides

Contraindications and Discontinuation Guidelines for GLP Medications

Written by SiPhox Health Research Team

Last updated: May 15, 2026

18 mins read

In this article

What This Article Includes
A Note on Terminology
Our Commitment to User Safety
Evidence-Based Guidance on Contraindications and Treatment Discontinuation
⚠️ When to Seek Urgent Medical Attention
Situations in which taking GLP medications is strongly discouraged, or where the medication should be stopped immediately if already in use.
Moderate / Relative Contraindications
Surgery, Anesthesia, and Procedural Sedation
Current Medications and Interaction Risk
Key Guidance for Users
Final Note
Disclaimer
References

What This Article Includes

Evidence-based guidance on contraindications for GLP-1 receptor agonists (e.g. semaglutide, liraglutide, dulaglutide) and the dual GIP/GLP-1 receptor agonist tirzepatide, and when to review treatment
A clear list of urgent symptoms that warrant immediate medical attention
Contraindications that are generally treatment-limiting (absolute) versus those requiring case-by-case medical evaluation (relative)
Pregnancy, contraception, and breastfeeding considerations, including medication-specific washout periods
Risks related to pancreatitis, gallbladder, kidney, and gastrointestinal conditions
Thyroid and genetic safety warnings (MTC, MEN2)
Allergy and hypersensitivity risks
Key medication interaction considerations, including absorption-related contraceptive interactions
Peri-procedure and anaesthesia considerations
Guidance on safe use and speaking with a prescribing physician

A Note on Terminology

In this article we refer to “GLP-1 and GLP-1/GIP medications” to reflect the fact that the most commonly prescribed agents in this group have different mechanisms. Semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide (Victoza, Saxenda), and dulaglutide (Trulicity) act on the GLP-1 receptor only. Tirzepatide (Mounjaro, Zepbound) acts on both the GLP-1 and the GIP (glucose-dependent insulinotropic polypeptide) receptors. Where a recommendation is specific to one medication or to a subset of this class, we note that explicitly.

Our Commitment to User Safety

At SiPhox, we understand that GLP-1 and GLP-1/GIP medications can play an important role in supporting weight management and metabolic health goals. At the same time, user safety must always come first.

We believe it is important for individuals using these medications to fully understand potential contraindications, risks, and warning signs associated with treatment.

Evidence-Based Guidance on Contraindications and Treatment Discontinuation

Below is a summary of contraindications and safety considerations for GLP-1 receptor agonists and tirzepatide as described in current clinical literature and prescribing guidelines.

These recommendations are based on published medical evidence and are intended to help users better understand situations in which treatment may not be appropriate or may require closer medical supervision.

While this information can support awareness and informed decision-making, it is not a substitute for individualised medical evaluation. If a user believes any of these contraindications may apply to them, or is considering stopping their medication for any reason, they should first speak with their prescribing physician.

A licensed clinician is best positioned to interpret these guidelines in the context of the user’s full medical history and determine whether continuation, adjustment, or discontinuation of therapy is appropriate and safe.

⚠️ When to Seek Urgent Medical Attention

Most side effects of GLP-1 and GLP-1/GIP medications are mild and resolve as the body adjusts. However, certain symptoms can indicate serious complications and should be treated as medical emergencies. Users should seek immediate medical assessment — typically through emergency services or the nearest emergency department — if they experience any of the following:

Possible pancreatitis

Severe, persistent abdominal pain, particularly in the upper abdomen
Pain radiating to the back
Severe or persistent nausea or vomiting, especially when combined with abdominal pain
Abdominal pain accompanied by fever or marked abdominal tenderness

Severe allergic or hypersensitivity reaction

Swelling of the face, lips, tongue, or throat
Difficulty breathing, wheezing, or tightness in the throat
Widespread rash, hives, or severe itching
Dizziness, fainting, or rapid heartbeat following injection

Severe gastrointestinal symptoms or dehydration

Persistent vomiting or inability to keep fluids down for more than 24 hours
Signs of dehydration: marked thirst, dark urine, very reduced urine output, dizziness on standing, confusion, or rapid heartbeat
Severe diarrhoea, particularly if combined with vomiting

Possible gallbladder complications

Sudden, severe upper-right or central abdominal pain, especially after meals
Pain radiating to the right shoulder or back
Fever combined with abdominal pain
Yellowing of the skin or eyes (jaundice)
Pale stools or dark urine

Possible kidney injury

A significant drop in urine output
New or worsening swelling in the legs or ankles
Confusion or marked fatigue, particularly in the context of vomiting or diarrhoea

If a user is unsure whether their symptoms are serious, the safest course is to seek medical assessment rather than wait. Users should not stop their medication on their own without first speaking with their prescribing physician unless instructed to do so in an emergency setting.

Contraindications:

Situations in which taking GLP medications is strongly discouraged, or where the medication should be stopped immediately if already in use.

This recommendation is based on the potential for clinically significant health risks that should be reviewed with your Primary Care Physician (PCP) prior to initiating or continuing this medication. If you have any concerns or develop new symptoms, please consult your PCP before making changes to your treatment plan. The following contraindications and precautions may include, but are not limited to, the conditions listed below:

1. Personal or Family History of Medullary Thyroid Carcinoma (MTC)

Most medications in this class — including semaglutide, liraglutide, dulaglutide, exenatide extended-release, and tirzepatide — carry a U.S. boxed warning relating to the potential risk of thyroid C-cell tumours. This warning is based on preclinical animal studies in which sustained exposure to certain GLP-1 receptor agonists was associated with the development of these tumours. While the direct risk in humans has not been definitively established, this precaution is well recognised in medical literature, prescribing information, and clinical guidelines.

Because of this established safety concern, these medications are generally considered contraindicated in users with:

A personal history of MTC
A family history of MTC

Healthcare providers are advised to carefully review a patient’s personal and family medical history before initiating treatment. Users should also promptly report symptoms that could suggest thyroid-related complications, including:

A lump or swelling in the neck
Persistent hoarseness
Difficulty swallowing
Shortness of breath

2. Multiple Endocrine Neoplasia Syndrome Type 2 (MEN2)

MEN2 is a hereditary endocrine disorder associated with a significantly increased risk of developing medullary thyroid carcinoma and other endocrine tumours. Because individuals with MEN2 already carry an elevated baseline risk for thyroid C-cell abnormalities, GLP-1 and GLP-1/GIP medications are generally considered contraindicated in this population.

This precaution is widely recognised in clinical practice and is included in FDA labelling and prescribing guidance for several medications in this class. Before prescribing treatment, healthcare providers typically assess for any known personal or family history of MEN2 or related endocrine cancers.

Users with MEN2 or suspected MEN2 should discuss all treatment options carefully with their endocrinologist or prescribing physician. In many cases, alternative therapies may be considered more appropriate depending on the patient’s overall medical history and risk profile.

3. History of Severe Hypersensitivity

A prior severe allergic or hypersensitivity reaction to a specific GLP-1 or GLP-1/GIP medication represents a strict contraindication to continued use of that medication and, in some cases, related medications within the same class. Although severe reactions are uncommon, they are well documented in medical literature and post-marketing safety reports.

Serious hypersensitivity reactions may include:

Facial or throat swelling (angioedema)
Difficulty breathing
Severe rash or hives
Anaphylaxis

Because allergic reactions can rapidly become life-threatening, users experiencing symptoms suggestive of a severe reaction should seek immediate medical attention (see urgent warning section above). Healthcare providers should also review any previous medication allergies or reactions before initiating therapy.

Even if symptoms appear mild initially, recurrent exposure after a significant hypersensitivity reaction may increase the risk of a more severe response in the future. For this reason, careful medical evaluation is essential before restarting or switching medications within this class after any suspected allergic event.

4. Pregnancy, Pregnancy Planning and Contraceptive Health

GLP-1 and GLP-1/GIP medications are not recommended during pregnancy. Human safety data are limited and animal studies of several agents in this class have demonstrated adverse fetal outcomes, including reduced fetal growth and developmental abnormalities at clinically relevant exposures. Intentional weight loss is also not recommended during pregnancy because it offers no benefit to a pregnant patient and may cause fetal harm.

A defining feature of these medications is their extended duration of action, which is why preconception planning is especially important. Recommended washout periods vary by medication because half-lives differ substantially:

Semaglutide (Ozempic, Wegovy, Rybelsus) — half-life approximately 1 week. The FDA label recommends discontinuation at least 2 months before a planned pregnancy.
Tirzepatide (Mounjaro, Zepbound) — half-life approximately 5 days. The FDA label recommends discontinuation at least 1 month before a planned pregnancy; some reproductive medicine literature suggests 25–35 days is a reasonable minimum, with longer intervals where feasible.
Liraglutide (Victoza, Saxenda) — half-life approximately 13 hours. Discontinuation at least 3 days before conception is generally considered sufficient based on its pharmacokinetics.
Dulaglutide (Trulicity) — long half-life of approximately 5 days; discontinuation roughly 1 month before conception is often recommended.

If a user becomes pregnant while taking any of these medications, the medication should be discontinued and the prescribing physician contacted promptly. The presence of the drug in early pregnancy is not, in itself, considered an indication for pregnancy termination, but it should be reviewed with an obstetric clinician. Several manufacturers maintain pregnancy exposure registries that users and their providers may wish to contact.

Recommendations:

Users planning pregnancy should discuss the timing of medication discontinuation with their healthcare provider well in advance of trying to conceive
Users who become pregnant while taking any medication in this class should notify their prescribing physician as soon as possible
Alternative diabetes or metabolic management strategies may be recommended during pregnancy depending on the individual’s clinical needs

Contraception (Important for Tirzepatide)

Because GLP-1 and GLP-1/GIP medications slow gastric emptying, the absorption of orally administered drugs — including oral contraceptive pills — may be reduced, particularly early in treatment and after each dose increase.

This is most explicitly addressed in the FDA labels for tirzepatide (Mounjaro and Zepbound), which advise that users of oral hormonal contraceptives:

Switch to a non-oral contraceptive method (e.g. intrauterine device, contraceptive implant, injection, patch, or vaginal ring), or
Add a barrier method of contraception (e.g. condoms)
For 4 weeks after initiating tirzepatide and for 4 weeks after each dose escalation

Non-oral hormonal methods are not expected to be affected by tirzepatide and do not require backup contraception based on this mechanism.

For other medications in this class (e.g. semaglutide, liraglutide), the prescribing labels do not contain an equivalent specific recommendation. However, because the underlying mechanism — delayed gastric emptying — is shared across the class to varying degrees, some clinicians take a similar precautionary approach during dose initiation and escalation, particularly for users in whom an unplanned pregnancy would be a significant concern. Users should discuss contraception planning with their prescribing physician.

Moderate / Relative Contraindications

The following conditions are considered moderate or relative contraindications. Treatment may still be appropriate in certain cases, but additional medical evaluation, monitoring, and risk-benefit assessment are often necessary.

Clinical decisions should always be individualised based on the user’s medical history, current health status, laboratory findings, and guidance from their prescribing physician.

1. Breastfeeding

There are currently insufficient human data to determine whether GLP-1 or GLP-1/GIP medications are excreted into breast milk or how they may affect a nursing infant. The FDA labels for both tirzepatide and semaglutide note that data are absent or limited in this area. Because of the limited evidence, caution is generally advised during breastfeeding.

Healthcare providers must weigh the potential benefits of treatment for the mother against any theoretical risks to the infant. In some situations, alternative therapies with more established safety data during lactation may be preferred.

Additional factors that may influence decision-making include:

The age and health status of the infant
The mother’s metabolic or diabetes-related health needs
The severity of obesity-related medical conditions
Whether the medication is being used primarily for weight management or glycaemic control

Recommendations:

Users should discuss breastfeeding plans with their prescribing physician before starting or continuing therapy
Careful monitoring and individualised medical guidance are recommended if treatment is continued during lactation

2. History of Pancreatitis

Cases of acute pancreatitis have been reported in individuals taking GLP-1 and GLP-1/GIP medications. A definitive causal relationship has not been fully established, and large randomised trials have not consistently shown an increased risk. Nonetheless, because pancreatitis can become severe and potentially life-threatening, caution is advised in users with a prior history of pancreatic disease or other significant risk factors.

Symptoms of pancreatitis may include:

Severe or persistent abdominal pain
Pain radiating to the back
Nausea and vomiting
Fever or abdominal tenderness

Pancreatitis is uncommon but potentially serious. Users who develop severe, persistent abdominal pain — particularly with nausea or vomiting — should seek urgent medical assessment.

Users with the following risk factors may require closer monitoring:

Prior pancreatitis
Gallstones or biliary disease
Heavy alcohol use
Elevated triglyceride levels, particularly severe hypertriglyceridaemia (commonly defined as triglyceride levels above 500 mg/dL, and especially above 1,000 mg/dL)
Certain metabolic or gastrointestinal disorders that may increase pancreatic stress or inflammation risk, including:
- Poorly controlled type 2 diabetes
- Obesity associated with metabolic syndrome
- Active gallbladder disease or gallstones
- Inherited lipid disorders, such as familial hypertriglyceridaemia

Users with these risk factors may require closer clinical monitoring and individualised evaluation before initiating or continuing therapy.

3. Severe Gastrointestinal Disease (e.g. Gastroparesis)

GLP-1 and GLP-1/GIP medications work in part by slowing gastric emptying, which contributes to appetite reduction and improved blood sugar control. However, this same mechanism may worsen symptoms in users with underlying gastrointestinal motility disorders such as gastroparesis.

In severe cases, delayed gastric emptying can interfere with hydration, nutrition, and the absorption of other oral medications. Because gastrointestinal side effects are among the most common adverse effects associated with this class, users with pre-existing digestive disorders often require careful assessment before treatment initiation.

Healthcare providers may consider:

Lower starting doses
Slower dose escalation
Alternative medications
Ongoing symptom monitoring

Users experiencing severe or worsening gastrointestinal symptoms — particularly persistent vomiting, inability to keep fluids down, or signs of dehydration — should contact their healthcare provider promptly or seek urgent care (see urgent warning section above).

4. Chronic Kidney Disease

Some GLP-1 and GLP-1/GIP medications may require caution in users with moderate to severe kidney impairment, particularly those at risk for dehydration or acute kidney injury. While several agents in this class can be used safely in certain stages of chronic kidney disease, severe gastrointestinal side effects such as vomiting or diarrhoea may worsen kidney function due to fluid loss and electrolyte imbalance.

Users with advanced kidney disease may be more vulnerable to:

Dehydration
Acute kidney injury
Electrolyte abnormalities
Reduced medication tolerance

Clinical monitoring may include:

Kidney function testing
Hydration assessment
Monitoring for gastrointestinal adverse effects
Medication dose review

Because recommendations vary between individual medications, treatment decisions should be based on the specific medication prescribed and the severity of kidney impairment.

5. Gallbladder Disease

GLP-1 and GLP-1/GIP medications have been associated with an increased risk of gallbladder-related complications, including gallstones and inflammation of the gallbladder. Rapid weight loss itself may also increase the likelihood of gallstone formation, which can make it difficult to distinguish medication-related effects from weight-loss-related risk factors.

Potential gallbladder complications may include:

Gallstones (cholelithiasis)
Gallbladder inflammation (cholecystitis)
Biliary colic
Bile duct obstruction

Symptoms that may require urgent medical evaluation include:

Upper abdominal pain, especially after eating
Pain radiating to the shoulder or back
Fever
Nausea or vomiting
Yellowing of the skin or eyes (jaundice)

Users with a prior history of gallbladder disease should discuss these risks with their healthcare provider before starting treatment. In some cases, additional monitoring or alternative therapies may be considered depending on the individual’s medical history and symptom severity.

Surgery, Anesthesia, and Procedural Sedation

Because GLP-1 and GLP-1/GIP medications slow gastric emptying, food and fluid can remain in the stomach for longer than expected. In the context of anaesthesia or procedural sedation, this can theoretically increase the risk of regurgitation and pulmonary aspiration (stomach contents entering the lungs) even after standard fasting periods.

Recommendations in this area have evolved. Earlier 2023 guidance from the American Society of Anesthesiologists suggested holding daily-dose medications on the day of a procedure and weekly-dose medications one week before. Updated multi-society guidance issued in October 2024 — endorsed by the American Society of Anesthesiologists, the American Gastroenterological Association, the American Society for Metabolic and Bariatric Surgery, the International Society of Perioperative Care of Patients with Obesity, and the Society of American Gastrointestinal and Endoscopic Surgeons — concluded that most patients can continue their medication before elective surgery, with risk-stratified precautions rather than blanket discontinuation.

The updated approach focuses on:

Shared decision-making between the user, the prescribing physician, the surgeon, and the anaesthesia team
Day-of-procedure assessment for symptoms suggestive of delayed gastric emptying (such as nausea, bloating, or recent vomiting)
A 24-hour clear liquid diet prior to the procedure for users considered at higher risk (e.g. those still in dose escalation, on higher doses, or with persistent gastrointestinal symptoms)
Anaesthetic plan adjustments where appropriate to minimise aspiration risk
Point-of-care gastric ultrasound in selected high-risk cases, where available, to assess gastric contents before sedation

Key user guidance:

Always inform the anaesthesia and surgical team that you are taking a GLP-1 or GLP-1/GIP medication, including the specific drug, dose, and timing of your most recent dose
Do not stop or hold your medication ahead of a procedure without confirmation from your prescribing physician and the procedural team — abrupt discontinuation may also have implications for glycaemic control
Follow any procedure-specific fasting or pre-procedure diet instructions provided by your care team
Mention this medication for any procedure involving sedation, including endoscopy, colonoscopy, dental work under sedation, and elective surgery

Current Medications and Interaction Risk

Before starting GLP-1 or GLP-1/GIP therapy, you should inform your clinician of all medications you are taking, including prescription drugs, over-the-counter treatments, and supplements. This is important because these medications slow gastric emptying and intestinal transit, which can affect how other drugs are absorbed and tolerated.

Special attention should be paid to the following categories:

Medications with narrow therapeutic windows, where small changes in blood levels can have significant effects
- Examples: warfarin, levothyroxine, lithium, digoxin
Medications requiring consistent absorption or timing, where altered absorption may reduce efficacy or stability
- Examples: levothyroxine, oral contraceptives, tacrolimus, certain antiepileptics
Oral hormonal contraceptives — see the dedicated contraception section above, particularly for tirzepatide
Diabetes medications that increase hypoglycaemia risk when combined
- Examples: insulin, sulfonylureas such as glipizide or gliclazide
Medications that affect gastrointestinal motility or are affected by it
- Examples: metoclopramide, loperamide, erythromycin
Users on complex polypharmacy or unstable regimens — for example, multiple cardiovascular, psychiatric, or endocrine medications with frequent dose adjustments
- Examples: antidepressants (sertraline, amitriptyline), antiepileptics (valproate, carbamazepine), antihypertensives (amlodipine, beta-blockers such as bisoprolol)

Because therapy can slow digestion, it may alter the timing, absorption, and overall effectiveness of co-administered medications, particularly during dose initiation and escalation. Careful monitoring and individualised dose adjustments may therefore be required under medical supervision.

Key Guidance for Users

Users taking GLP-1 or GLP-1/GIP medications should:

Be informed of all potential contraindications before starting treatment
Recognise the urgent warning signs above and know when to seek emergency care
Report new or worsening symptoms promptly to their physician
Inform any clinician treating them — including anaesthesia and dental teams — that they are taking the medication
Maintain regular follow-up with their prescribing healthcare provider
Never stop or adjust medication without medical guidance, unless instructed to do so as part of an emergency response

Final Note

GLP-1 and GLP-1/GIP medications can offer significant benefits, but they must be used responsibly. Awareness of contraindications, early recognition of warning signs, and clear communication with all members of a user’s care team are essential to safe use.

Users should always consult their prescribing physician to determine whether therapy is appropriate for their specific medical history and to decide when adjustment or discontinuation is necessary.

Disclaimer

This article is intended for general educational purposes only and does not constitute medical advice. It is not a substitute for individualised diagnosis, treatment, or recommendations from a qualified healthcare professional. Clinical guidelines, prescribing information, and the evidence base for these medications continue to evolve; users should rely on their prescribing physician for current, personalised guidance. SiPhox does not assume responsibility for clinical decisions made on the basis of this article. If you believe you are experiencing a medical emergency, contact emergency services or go to the nearest emergency department.